COMPASS: Rivaroxaban Success in Secondary CV Prevention COMPASS: Rivaroxaban Success in Secondary CV Prevention

The combination of a low dose of the factor Xa inhibitor rivaroxaban in combination with aspirin was associated with a reduction in ischemic events and mortality and a superior net clinical benefit, balancing the bleeding risk in patients with stable atherosclerotic disease.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news